{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:58:20Z","timestamp":1789628300974,"version":"build-2803163510"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejmech.2026.118779","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T07:34:15Z","timestamp":1773992055000},"page":"118779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Medicinal chemistry strategies targeting viral proteases: From classical design to next-generation therapeutics"],"prefix":"10.1016","volume":"310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7702-9379","authenticated-orcid":false,"given":"Mansour S.","family":"Alturki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Gomaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118779_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.631736","article-title":"Pandemics throughout history","volume":"11","author":"Piret","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118779_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41579-021-00639-z","article-title":"Infectious disease in an era of global change","volume":"20","author":"Baker","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118779_bib3","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/jmv.26163","article-title":"The epidemiology and clinical characteristics of co\u2010infection of SARS\u2010CoV\u20102 and influenza viruses in patients during COVID\u201019 outbreak","volume":"92","author":"Yue","year":"2020","journal-title":"J. Med. Virol."},{"issue":"21","key":"10.1016\/j.ejmech.2026.118779_bib4","doi-asserted-by":"crossref","first-page":"11754","DOI":"10.1128\/JVI.01348-12","article-title":"Broad-spectrum antivirals against 3C or 3C-Like proteases of picornaviruses, noroviruses, and coronaviruses","volume":"86","author":"Kim","year":"2012","journal-title":"J. Virol."},{"issue":"6298","key":"10.1016\/j.ejmech.2026.118779_bib5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1126\/science.aag2419","article-title":"Crystal structure of zika virus NS2B-NS3 protease in complex with a boronate inhibitor","volume":"353","author":"Lei","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118779_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118779_bib7","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1128\/jvi.65.2.922-930.1991","article-title":"Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein","volume":"65","author":"Tritch","year":"1991","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118779_bib8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/pathogens10020102","article-title":"Identification of cleavage sites proteolytically processed by NS2B-NS3 protease in polyprotein of Japanese encephalitis virus","volume":"10","author":"Wahaab","year":"2021","journal-title":"Pathogens"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118779_bib9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12033-021-00299-7","article-title":"Cell-based high-throughput screening protocol for discovering antiviral inhibitors against SARS-COV-2 main protease (3CLpro)","volume":"63","author":"Rothan","year":"2021","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.ejmech.2026.118779_bib10","doi-asserted-by":"crossref","first-page":"5762","DOI":"10.3390\/ijms22115762","article-title":"Protease inhibition\u2014an established strategy to combat infectious diseases","volume":"22","author":"Sojka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118779_bib11","doi-asserted-by":"crossref","first-page":"30433","DOI":"10.1074\/jbc.R800035200","article-title":"Proteases: multifunctional enzymes in life and disease","volume":"283","author":"L\u00f3pez-Ot\u00edn","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"22","key":"10.1016\/j.ejmech.2026.118779_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01265-20","article-title":"Development of a fluorescence-based, high-throughput SARS-CoV-2 3CL pro reporter assay","volume":"94","author":"Froggatt","year":"2020","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118779_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/srep14753","article-title":"Kinetic characterization of trans-proteolytic activity of Chikungunya virus capsid protease and development of a FRET-based HTS assay","volume":"5","author":"Aggarwal","year":"2015","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118779_bib14","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1021\/acscentsci.1c00519","article-title":"Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-Based reporter assay","volume":"7","author":"Ma","year":"2021","journal-title":"ACS Cent. Sci."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118779_bib15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.tim.2017.07.001","article-title":"Zika virus protease: an antiviral drug target","volume":"25","author":"Kang","year":"2017","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ejmech.2026.118779_bib16","doi-asserted-by":"crossref","first-page":"38321","DOI":"10.1074\/jbc.M111.260026","article-title":"Asparagine peptide lyases","volume":"286","author":"Rawlings","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118779_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2477\/jchemsoft.7.103","article-title":"A study on docking mode of HIV protease and their inhibitors","volume":"7","author":"Akaho","year":"2001","journal-title":"J. Chem. Software"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118779_bib18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1107\/S0907444903029676","article-title":"Rapid screening for HIV-1 protease inhibitor leads through X-ray diffraction","volume":"60","author":"Pillai","year":"2004","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118779_bib19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.6026\/97320630010227","article-title":"Evaluation of novel saquinavir analogs for resistance mutation compatibility and potential as an HIV-protease inhibitor drug","volume":"10","author":"Jayaswal","year":"2014","journal-title":"Bioinformation"},{"issue":"S1","key":"10.1016\/j.ejmech.2026.118779_bib20","first-page":"1","article-title":"Exploring the mechanisms of drug resistance with a 3D molecular model of HIV protease","volume":"34","author":"Gilmore","year":"2020","journal-title":"FASEB J."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118779_bib21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1747-0285.2006.00382.x","article-title":"Optimization and computational evaluation of a series of potential active site inhibitors of the V82F\/I84V drug\u2010resistant mutant of HIV\u20101 protease: an application of the relaxed complex method of structure\u2010based drug design","volume":"67","author":"Perryman","year":"2006","journal-title":"Chem. Biol. Drug Des."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118779_bib22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/COH.0b013e3283136cee","article-title":"New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors","volume":"3","author":"Nalam","year":"2008","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"26","key":"10.1016\/j.ejmech.2026.118779_bib23","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.2174\/092986707782360141","article-title":"Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors","volume":"14","author":"Mastrolorenzo","year":"2007","journal-title":"Curr. Med. Chem."},{"issue":"25","key":"10.1016\/j.ejmech.2026.118779_bib24","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.ejmech.2026.118779_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127377","article-title":"The SARS-CoV-2 main protease as drug target","volume":"30","author":"Ullrich","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118779_bib26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1021\/ar7001232","article-title":"Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance","volume":"41","author":"Ghosh","year":"2007","journal-title":"Accounts of Chemical Research"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118779_bib27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dkh029","article-title":"Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients","volume":"53","author":"Zeldin","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118779_bib28","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118779_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118779_bib30","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1073\/pnas.96.7.3900","article-title":"Choroid plexus epithelial expression of MDR 1 P glycoprotein and multidrug resistance-associated protein contribute to the blood\u2013cerebrospinal-fluid drug-permeability barrier","volume":"96","author":"Rao","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118779_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/pharmaceutics10020039","article-title":"Nose-to-Brain delivery of antiviral drugs: a way to overcome their active efflux?","volume":"10","author":"Dalpiaz","year":"2018","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.ejmech.2026.118779_bib32","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1086\/498310","article-title":"Efficacy of cerebrospinal fluid (CSF)\u2013penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma","volume":"41","author":"Antinori","year":"2005","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118779_bib33","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nrd3053","article-title":"Emerging principles in protease-based drug discovery","volume":"9","author":"Dr\u0105g","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118779_bib34","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118779_bib35","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1021\/acs.jmedchem.2c00123","article-title":"Peptidomimetics: an overview of recent medicinal chemistry efforts toward the discovery of novel small molecule inhibitors","volume":"65","author":"Petri","year":"2022","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118779_bib36","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2174\/0929867013372715","article-title":"Macrocycles mimic the extended peptide conformation recognized by aspartic, serine, cysteine and metallo proteases","volume":"8","author":"Tyndall","year":"2001","journal-title":"Curr. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118779_bib37","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/nchem.2636","article-title":"Oxadiazole grafts in peptide macrocycles","volume":"8","author":"Frost","year":"2016","journal-title":"Nat. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118779_bib38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2174\/1389557023405747","article-title":"Mimetics of the peptide \u03b2-Strand","volume":"2","author":"Glenn","year":"2002","journal-title":"Mini Rev. Med. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2026.118779_bib39","doi-asserted-by":"crossref","first-page":"16902","DOI":"10.1021\/acs.jmedchem.2c01716","article-title":"Discovery and crystallographic studies of nonpeptidic piperazine derivatives as covalent SARS-CoV-2 main protease inhibitors","volume":"65","author":"Gao","year":"2022","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2026.118779_bib40","doi-asserted-by":"crossref","first-page":"11104","DOI":"10.1128\/JVI.76.21.11104-11112.2002","article-title":"Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults","volume":"76","author":"Barbour","year":"2002","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118779_bib41","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3390\/pharmaceutics13111798","article-title":"Past HIV-1 medications and the current status of combined antiretroviral therapy options for HIV-1 patients","volume":"13","author":"Weichseldorfer","year":"2021","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118779_bib42","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1128\/AAC.00341-16","article-title":"Fullerene derivatives strongly inhibit HIV-1 replication by affecting virus maturation without impairing protease activity","volume":"60","author":"Martinez","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118779_bib43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.antiviral.2012.11.005","article-title":"Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease","volume":"97","author":"Kim","year":"2012","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118779_bib44","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11904-014-0253-5","article-title":"Antiretrovirals for primary HIV prevention: the current status of Pre- and post-exposure prophylaxis","volume":"12","author":"Krakower","year":"2015","journal-title":"Curr. HIV AIDS Rep."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118779_bib45","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/cmdc.202000101","article-title":"Pharmacokinetic parameters of HIV\u20101 protease inhibitors","volume":"15","author":"Nascimento","year":"2020","journal-title":"ChemMedChem"},{"issue":"6575","key":"10.1016\/j.ejmech.2026.118779_bib46","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118779_bib47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/pharmaceutics16020217","article-title":"The design, synthesis and mechanism of action of paxlovid, a protease inhibitor drug combination for the treatment of COVID-19","volume":"16","author":"Bege","year":"2024","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118779_bib48","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/1860","article-title":"Conserved mode of peptidomimetic inhibition and substrate recognition of human cytomegalovirus protease","volume":"5","author":"Tong","year":"1998","journal-title":"Nat. Struct. Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118779_bib49","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ejoc.201801087","article-title":"From cyclic ketimines to \u03b1\u2010Substituted cyclic amino acids and their derivatives: influence of ring size and substituents on stability and reactivity of cyclic aminonitriles","volume":"2019","author":"Voznesenskaia","year":"2018","journal-title":"Eur. J. Org Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118779_bib50","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1021\/acsinfecdis.0c00815","article-title":"Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19","volume":"7","author":"Steuten","year":"2021","journal-title":"ACS Infect. Dis."},{"issue":"24","key":"10.1016\/j.ejmech.2026.118779_bib51","doi-asserted-by":"crossref","first-page":"10807","DOI":"10.1021\/acs.jmedchem.6b00319","article-title":"Unusual amino acids in medicinal chemistry","volume":"59","author":"Blaskovich","year":"2016","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118779_bib52","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1021\/acs.jmedchem.2c02130","article-title":"Factor XIA inhibitors in anticoagulation therapy: recent advances and perspectives","volume":"66","author":"Xie","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118779_bib53","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/AAC.00855-10","article-title":"Novel dengue virus-specific NS2B\/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay","volume":"55","author":"Yang","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"29","key":"10.1016\/j.ejmech.2026.118779_bib54","doi-asserted-by":"crossref","first-page":"6646","DOI":"10.1021\/bi00144a004","article-title":"Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, x-ray crystallography, and infected T-cell assays","volume":"31","author":"Dreyer","year":"1992","journal-title":"Biochemistry"},{"issue":"17","key":"10.1016\/j.ejmech.2026.118779_bib55","doi-asserted-by":"crossref","first-page":"6746","DOI":"10.1021\/jo050740w","article-title":"Stereoselective synthesis of constrained azacyclic hydroxyethylene isosteres as aspartic protease inhibitors: dipolar cycloaddition and related methodologies toward branched pyrrolidine and pyrrolidinone carboxylic acids","volume":"70","author":"Hanessian","year":"2005","journal-title":"J. Org. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118779_bib56","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1039\/b901718f","article-title":"\u03a8[CH(CF3)NH]Gly-peptides: synthesis and conformation analysis","volume":"7","author":"Molteni","year":"2009","journal-title":"Org. Biomol. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118779_bib57","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/cbic.200300724","article-title":"Rapid diversity\u2010oriented synthesis in microtiter plates for in situ screening of HIV protease inhibitors","volume":"4","author":"Brik","year":"2003","journal-title":"Chembiochem"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118779_bib58","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1021\/jm050520a","article-title":"Potent 7-Hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease","volume":"49","author":"Chen","year":"2005","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118779_bib59","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/s41401-018-0046-2","article-title":"GP205, a new hepatitis C virus NS3\/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo","volume":"39","author":"Zhai","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2026.118779_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.896588","article-title":"Micro-PET imaging of hepatitis C virus NS3\/4A protease activity using a protease-activatable retention probe","volume":"13","author":"Chuang","year":"2022","journal-title":"Front. Microbiol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118779_bib61","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cld.332","article-title":"Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment","volume":"3","author":"Lin","year":"2014","journal-title":"Clinical Liver Disease"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118779_bib62","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1021\/acschembio.5b00647","article-title":"Structural and thermodynamic effects of macrocyclization in HCV NS3\/4A inhibitor MK-5172","volume":"11","author":"Soumana","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"16","key":"10.1016\/j.ejmech.2026.118779_bib63","doi-asserted-by":"crossref","first-page":"11972","DOI":"10.1021\/acs.jmedchem.1c00554","article-title":"Discovery of quinoxaline-based P1\u2013P3 macrocyclic NS3\/4A protease inhibitors with potent activity against drug-resistant hepatitis C virus variants","volume":"64","author":"Rao","year":"2021","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118779_bib64","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00172-20","article-title":"Avoiding drug resistance by substrate envelope-guided design: toward potent and robust HCV NS3\/4A protease inhibitors","volume":"11","author":"Matthew","year":"2020","journal-title":"mBio"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118779_bib65","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1021\/cb400100g","article-title":"Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3\/4A protease inhibitors to drug resistance","volume":"8","author":"Ali","year":"2013","journal-title":"ACS Chem. Biol."},{"issue":"20","key":"10.1016\/j.ejmech.2026.118779_bib66","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1021\/ja0256461","article-title":"Conformationally constrained macrocycles that mimic tripeptide \u03b2-Strands in water and aprotic solvents","volume":"124","author":"Reid","year":"2002","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118779_bib67","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40588-024-00229-6","article-title":"SARS-CoV-2 resistance to small molecule inhibitors","volume":"11","author":"Lopez","year":"2024","journal-title":"Curr. Clin. Microbiol. Rep."},{"issue":"22","key":"10.1016\/j.ejmech.2026.118779_bib68","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1021\/acs.jcim.3c01269","article-title":"Discovery of Nirmatrelvir resistance mutations in SARS-CoV-2 3CLpro: a computational-experimental approach","volume":"63","author":"Havranek","year":"2023","journal-title":"J. Chem. Inf. Model."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118779_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/mog2.56","article-title":"Development of covalent inhibitors: principle, design, and application in cancer","volume":"2","author":"Zheng","year":"2023","journal-title":"MedComm \u2013 Oncology"},{"key":"10.1016\/j.ejmech.2026.118779_bib70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cbpa.2019.02.010","article-title":"Reactive-cysteine profiling for drug discovery","volume":"50","author":"Maurais","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118779_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-42102-y","article-title":"Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118779_bib72","article-title":"SARS\u2010CoV\u20102 main protease inhibitors: what is moving in the field of peptides and peptidomimetics?","volume":"29","author":"Algar","year":"2022","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.ejmech.2026.118779_bib73","author":"Unoh"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118779_bib74","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1021\/acs.jmedchem.1c00616","article-title":"Peptidomimetic \u03b1-Acyloxymethylketone warheads with six-membered lactam P1 glutamine mimic: SARS-CoV-2 3CL protease inhibition, coronavirus antiviral activity, and in vitro biological stability","volume":"65","author":"Bai","year":"2021","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2026.118779_bib75","doi-asserted-by":"crossref","first-page":"10423","DOI":"10.1002\/anie.202016961","article-title":"Targeting the main protease of SARS\u2010CoV\u20102: from the establishment of high throughput screening to the design of tailored inhibitors","volume":"60","author":"Breidenbach","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.118779_bib76","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.3390\/v14092075","article-title":"Structural basis for the inhibition of coronaviral main proteases by a benzothiazole-based inhibitor","volume":"14","author":"Hu","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.118779_bib77","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.bmc.2019.04.002","article-title":"Characterising covalent warhead reactivity","volume":"27","author":"Martin","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118779_bib78","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.3390\/ijms24087226","article-title":"Investigation of the compatibility between warheads and peptidomimetic sequences of protease inhibitors\u2014A comprehensive reactivity and selectivity study","volume":"24","author":"M\u00fcller","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118779_bib79","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1021\/acsmedchemlett.2c00260","article-title":"A warhead substitution study on the coronavirus main protease inhibitor nirmatrelvir","volume":"13","author":"Vankadara","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118779_bib80","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118779_bib81","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/17460441.2022.2034783","article-title":"Electrophilic warheads in covalent drug discovery: an overview","volume":"17","author":"P\u00e9czka","year":"2022","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118779_bib82","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41589-020-0501-5","article-title":"Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles","volume":"16","author":"Eaton","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118779_bib83","doi-asserted-by":"crossref","first-page":"20407","DOI":"10.1021\/jacs.9b10769","article-title":"Diacylfuroxans are masked nitrile oxides that inhibit GPX4 covalently","volume":"141","author":"Eaton","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.118779_bib84","doi-asserted-by":"crossref","first-page":"11267","DOI":"10.1021\/acs.jmedchem.1c00628","article-title":"Self-masked aldehyde inhibitors: a novel strategy for inhibiting cysteine proteases","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118779_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.867928","article-title":"Self-masked aldehyde inhibitors of human cathepsin L are potent Anti-CoV-2 agents","volume":"10","author":"Zhu","year":"2022","journal-title":"Front. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2026.118779_bib86","doi-asserted-by":"crossref","first-page":"16505","DOI":"10.1021\/acs.jmedchem.4c01346","article-title":"Structure activity of \u03b2-Amidomethyl vinyl sulfones as covalent inhibitors of chikungunya nsP2 Cysteine protease with antialphavirus activity","volume":"67","author":"Ghoshal","year":"2024","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118779_bib87","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/AAC.04227-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3\/4A protease inhibitor ABT-450","volume":"59","author":"Tam","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118779_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002832","article-title":"The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors","volume":"8","author":"Romano","year":"2012","journal-title":"PLoS Pathog."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118779_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087077","article-title":"Computational study on the inhibitor binding mode and allosteric regulation mechanism in hepatitis C virus NS3\/4A protein","volume":"9","author":"Xue","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118779_bib90","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01620-17","article-title":"In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3\/4A protease inhibitor glecaprevir","volume":"62","author":"Ng","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6542","key":"10.1016\/j.ejmech.2026.118779_bib91","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1126\/science.abf7945","article-title":"X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease","volume":"372","author":"G\u00fcnther","year":"2021","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118779_bib92","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.50.3.899-909.2006","article-title":"Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease","volume":"50","author":"Perni","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"17","key":"10.1016\/j.ejmech.2026.118779_bib93","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.1021\/jacs.9b02505","article-title":"Discovery, X-ray crystallography and antiviral activity of allosteric inhibitors of flavivirus NS2B-NS3 protease","volume":"141","author":"Yao","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.118779_bib94","article-title":"Allosteric quinoxaline-based inhibitors of the flavivirus NS2B\/NS3 protease","volume":"131","author":"Zephyr","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118779_bib95","doi-asserted-by":"crossref","DOI":"10.1199\/tab.0174","article-title":"The ubiquitination machinery of the ubiquitin system","volume":"12","author":"Callis","year":"2014","journal-title":"Arab. Book"},{"key":"10.1016\/j.ejmech.2026.118779_bib96","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1093\/emboj\/17.24.7151","article-title":"The ubiquitin-proteasome pathway: on protein death and cell life","volume":"17","author":"Ciechanover","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2026.118779_bib97","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.4161\/cc.10.18.17191","article-title":"Terminating protein ubiquitination","volume":"10","author":"Stringer","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2026.118779_bib98","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.it.2021.12.005","article-title":"K63 ubiquitination in immune signaling","volume":"43","author":"Madiraju","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ejmech.2026.118779_bib99","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrm2630","article-title":"Molecular mechanisms of proteasome assembly","volume":"10","author":"Murata","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118779_bib100","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41467-023-36246-0","article-title":"Accelerating inhibitor discovery for deubiquitinating enzymes","volume":"14","author":"Chan","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118779_bib101","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41586-020-2457-8","article-title":"Envelope protein ubiquitination drives entry and pathogenesis of zika virus","volume":"585","author":"Giraldo","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118779_bib102","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.3390\/v13102029","article-title":"USP38 inhibits zika virus infection by removing envelope protein ubiquitination","volume":"13","author":"Wang","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.118779_bib103","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1084\/jem.20172026","article-title":"USP38 critically promotes asthmatic pathogenesis by stabilizing JunB protein","volume":"215","author":"Chen","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2026.118779_bib104","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40659-018-0201-8","article-title":"The deubiquitinase USP38 affects cellular functions through interacting with LSD1","volume":"51","author":"Liu","year":"2018","journal-title":"Biol. Res."},{"key":"10.1016\/j.ejmech.2026.118779_bib105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2026.118779_bib106","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.chembiol.2022.10.003","article-title":"Bortezomib inhibits ZIKV\/DENV by interfering with viral polyprotein cleavage via the ERAD pathway","volume":"30","author":"Ci","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118779_bib107","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.ejmech.2026.118779_bib108","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118779_bib109","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.290","article-title":"PROTACs: a novel strategy for cancer drug discovery and development","volume":"4","author":"Han","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2026.118779_bib110","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13535","article-title":"Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2\/COVID-19","volume":"74","author":"Marinella","year":"2020","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ejmech.2026.118779_bib111","article-title":"Indomethacin has a potent antiviral activity against SARS CoV-2 in vitro and canine coronavirus in vivo","author":"Xu","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejmech.2026.118779_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113814","article-title":"Indomethacin-based PROTACs as pan-coronavirus antiviral agents","volume":"226","author":"Desantis","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118779_bib113","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1021\/acs.jmedchem.3c02416","article-title":"Discovery of first-in-class PROTAC degraders of SARS-COV-2 main protease","volume":"67","author":"Alugubelli","year":"2024","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118779_bib114","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1021\/acsmedchemlett.3c00498","article-title":"Development of a GC-376 based peptidomimetic PROTAC as a degrader of 3-Chymotrypsin-like protease of SARS-COV-2","volume":"15","author":"Grifagni","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118779_bib115","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1039\/D1CB00011J","article-title":"Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation","volume":"2","author":"Bond","year":"2021","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118779_bib116","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312858","article-title":"Development of a PROTAC-based targeting strategy provides a mechanistically unique mode of anti-cytomegalovirus activity","volume":"22","author":"Hahn","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118779_bib117","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.3390\/ijms22062935","article-title":"Cyclin-dependent kinases (CDK) and their role in diseases development\u2013review","volume":"22","author":"\u0141ukasik","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118779_bib118","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.1152095","article-title":"Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function","volume":"320","author":"Hume","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118779_bib119","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1099\/jgv.0.000931","article-title":"Protein kinases responsible for the phosphorylation of the nuclear egress core complex of human cytomegalovirus","volume":"98","author":"Sonntag","year":"2017","journal-title":"J. Gen. Virol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118779_bib120","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/molecules29010225","article-title":"Computer-aided prediction of the interactions of viral proteases with antiviral drugs: antiviral potential of broad-spectrum drugs","volume":"29","author":"Ren","year":"2023","journal-title":"Molecules"},{"issue":"7811","key":"10.1016\/j.ejmech.2026.118779_bib121","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118779_bib122","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2174\/138161206776361110","article-title":"Antiviral drug discovery targeting to viral proteases","volume":"12","author":"Hsu","year":"2006","journal-title":"Curr. Pharm. Des."},{"issue":"46","key":"10.1016\/j.ejmech.2026.118779_bib123","doi-asserted-by":"crossref","first-page":"19306","DOI":"10.1021\/jacs.1c10588","article-title":"Concordance of X-ray and AlphaFold2 models of SARS-CoV-2 main protease with residual dipolar couplings measured in solution","volume":"143","author":"Robertson","year":"2021","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118779_bib124","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-86471-0","article-title":"Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity","volume":"11","author":"Weng","year":"2021","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118779_bib125","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1021\/acs.jpclett.0c00994","article-title":"In silico exploration of the molecular mechanism of clinically oriented drugs for possibly inhibiting SARS-CoV-2\u2019s main protease","volume":"11","author":"Huynh","year":"2020","journal-title":"J. Phys. Chem. Lett."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118779_bib126","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.3390\/cimb45040240","article-title":"Using AlphaFold predictions in viral research","volume":"45","author":"Gutnik","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118779_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105920","article-title":"How good are AlphaFold models for docking-based virtual screening?","volume":"26","author":"Scardino","year":"2022","journal-title":"iScience"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118779_bib128","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","article-title":"ColabFold: making protein folding accessible to all","volume":"19","author":"Mirdita","year":"2022","journal-title":"Nat. Methods"},{"issue":"14","key":"10.1016\/j.ejmech.2026.118779_bib129","doi-asserted-by":"crossref","first-page":"6906","DOI":"10.1128\/JVI.01900-05","article-title":"Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity","volume":"80","author":"Foulkes","year":"2006","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118779_bib130","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1110\/ps.03468904","article-title":"HIV\u20101 protease molecular dynamics of a wild\u2010type and of the V82F\/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs","volume":"13","author":"Perryman","year":"2004","journal-title":"Protein Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118779_bib131","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1007\/s11030-021-10211-9","article-title":"Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation","volume":"25","author":"Gogoi","year":"2021","journal-title":"Mol. Divers."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118779_bib132","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1007\/s12010-021-03615-8","article-title":"Synthesis and identification of novel potential molecules against COVID-19 main protease through structure-guided virtual screening approach","volume":"193","author":"Bakri","year":"2021","journal-title":"Appl. Biochem. Biotechnol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118779_bib133","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1021\/acsomega.1c05569","article-title":"Myricetin allosterically inhibits the dengue NS2B-NS3 protease by disrupting the active and locking the inactive conformations","volume":"7","author":"Dang","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.118779_bib134","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.antiviral.2018.12.002","article-title":"Inhibition of dengue virus by curcuminoids","volume":"162","author":"Balasubramanian","year":"2019","journal-title":"Antivir. Res."},{"issue":"13","key":"10.1016\/j.ejmech.2026.118779_bib135","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1039\/D1SC05892D","article-title":"Computationally driven discovery of SARS-CoV-2 mproinhibitors: from design to experimental validation","volume":"13","author":"Khoury","year":"2022","journal-title":"Chem. Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118779_bib136","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1021\/jacsau.3c00185","article-title":"Dynamical nonequilibrium molecular dynamics simulations identify allosteric sites and positions associated with drug resistance in the SARS-CoV-2 main protease","volume":"3","author":"Chan","year":"2023","journal-title":"JACS Au"},{"issue":"44","key":"10.1016\/j.ejmech.2026.118779_bib137","doi-asserted-by":"crossref","first-page":"27381","DOI":"10.1073\/pnas.2010470117","article-title":"Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs","volume":"117","author":"Li","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118779_bib138","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2024420118","article-title":"Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors","volume":"118","author":"Ma","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"679","key":"10.1016\/j.ejmech.2026.118779_bib139","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq4064","article-title":"S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters","volume":"15","author":"Sasaki","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118779_bib140","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.3390\/v15102052","article-title":"Pharmacokinetic and pharmacodynamic analysis of the 3CL protease inhibitor ensitrelvir in a SARS-COV-2 infection mouse model","volume":"15","author":"Fukao","year":"2023","journal-title":"Viruses"},{"issue":"Supplement_2","key":"10.1016\/j.ejmech.2026.118779_bib141","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad500.599","article-title":"530. Population pharmacokinetic analysis of ensitrelvir, an inhibitor of 3C-like (3CL) protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for patients with SARS-Cov-2 infection","volume":"10","author":"Ishibashi","year":"2023","journal-title":"Open Forum Infect. Dis."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118779_bib142","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.04068-24","article-title":"Molecular mechanisms of drug resistance and compensation in SARS-CoV-2 main protease: the interplay between E166 and L50","volume":"16","author":"Zvornicanin","year":"2025","journal-title":"mBio"},{"issue":"30","key":"10.1016\/j.ejmech.2026.118779_bib143","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adl4013","article-title":"In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance","volume":"10","author":"Zhu","year":"2024","journal-title":"Sci. Adv."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118779_bib145","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3390\/v16121926","article-title":"Discovery of potent dengue virus NS2B-NS3 protease inhibitors among glycyrrhizic acid conjugates with amino acids and dipeptides esters","volume":"16","author":"Lin","year":"2024","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118779_bib146","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1021\/jm9011559","article-title":"Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach","volume":"53","author":"Sun","year":"2009","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118779_bib147","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/mp900036s","article-title":"Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys","volume":"6","author":"Durand\u2010Gasselin","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2026.118779_bib148","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2015.07.003","article-title":"Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever","volume":"121","author":"Gowen","year":"2015","journal-title":"Antivir. Res."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118779_bib149","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/jm0303812","article-title":"Lessons learned from marketed and investigational prodrugs","volume":"47","author":"Ettmayer","year":"2004","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118779_bib150","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1073\/pnas.92.7.2484","article-title":"ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans","volume":"92","author":"Kempf","year":"1995","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118779_bib151","doi-asserted-by":"crossref","DOI":"10.1093\/toxres\/tfaf054","article-title":"Use of new approach methodology for hepatic safety assessment of covalent inhibitor drug candidates","volume":"14","author":"Amberntsson","year":"2025","journal-title":"Toxicol. Res."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118779_bib152","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1021\/acs.jmedchem.8b01153","article-title":"Emerging and Re-Emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology","volume":"62","author":"Gehringer","year":"2018","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2026.118779_bib153","doi-asserted-by":"crossref","first-page":"10497","DOI":"10.1021\/acs.jmedchem.9b00683","article-title":"Can cysteine protease cross-class inhibitors achieve selectivity?","volume":"62","author":"Cianni","year":"2019","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118779_bib154","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1021\/acs.jcim.7b00553","article-title":"Expanding the armory: predicting and tuning covalent warhead reactivity","volume":"57","author":"Lonsdale","year":"2017","journal-title":"J. Chem. Inf. Model."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118779_bib155","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/cts.13292","article-title":"PF\u201007321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: implications for COVID\u201019 patients","volume":"15","author":"Hau","year":"2022","journal-title":"Clin. Transl. Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118779_bib156","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.3390\/ijms25084376","article-title":"The inhibition of NS2B\/NS3 protease: a new therapeutic opportunity to treat dengue and zika virus infection","volume":"25","author":"Starvaggi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118779_bib157","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12551-019-00508-3","article-title":"Proteases from dengue, west nile and zika viruses as drug targets","volume":"11","author":"Nitsche","year":"2019","journal-title":"Biophysical Reviews"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118779_bib158","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/bioengineering10010100","article-title":"In-Silico lead druggable compounds identification against SARS COVID-19 main protease target from In-House, Chembridge and Zinc databases by structure-based virtual screening, molecular docking and molecular dynamics simulations","volume":"10","author":"Ghufran","year":"2023","journal-title":"Bioengineering"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118779_bib159","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00044-022-02951-6","article-title":"The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations","volume":"31","author":"Joyce","year":"2022","journal-title":"Med. Chem. Res."},{"issue":"679","key":"10.1016\/j.ejmech.2026.118779_bib160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq4064","article-title":"S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters","volume":"15","author":"Sasaki","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118779_bib161","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1021\/acsomega.2c03881","article-title":"Novel investigational Anti-SARS-CoV-2 agent ensitrelvir \u201cS-217622\u201d: a very promising potential universal broad-spectrum antiviral at the therapeutic frontline of coronavirus species","volume":"8","author":"Eltayb","year":"2023","journal-title":"ACS Omega"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118779_bib162","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3390\/biomedicines9081044","article-title":"Structure and dynamics of zika virus protease and its insights into inhibitor design","volume":"9","author":"Li","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118779_bib163","article-title":"Characterizing early drug resistance-related events using geometric ensembles from HIV protease dynamics","volume":"8","author":"Amamuddy","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118779_bib167","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.antiviral.2009.10.003","article-title":"Fifteen years of HIV protease inhibitors: raising the barrier to resistance","volume":"85","author":"Wensing","year":"2009","journal-title":"Antivir. Res."},{"issue":"34","key":"10.1016\/j.ejmech.2026.118779_bib164","doi-asserted-by":"crossref","first-page":"11956","DOI":"10.1021\/ja504096m","article-title":"Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease","volume":"136","author":"Ragland","year":"2014","journal-title":"J. Am. Chem. Soc."},{"issue":"45","key":"10.1016\/j.ejmech.2026.118779_bib165","doi-asserted-by":"crossref","first-page":"15993","DOI":"10.1073\/pnas.1414063111","article-title":"Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease","volume":"111","author":"\u00d6zen","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118779_bib166","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/prot.25534","article-title":"Exploring the conformational landscapes of HIV protease structural ensembles using principal component analysis","volume":"86","author":"Hassan","year":"2018","journal-title":"Proteins: Struct., Funct., Bioinf."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T02:44:07Z","timestamp":1775616247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":166,"alternative-id":["S0223523426002242"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118779","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medicinal chemistry strategies targeting viral proteases: From classical design to next-generation therapeutics","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118779"}}